Close this search box.

Hexiris Welcomes Dr. Paul Harasymowycz to Its Scientific Committee | BioSpace

DIEPPE, New Brunswick, April 02, 2024 (GLOBE NEWSWIRE) — Hexiris Inc. (“Hexiris” or the “Company”), a medical device firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that Dr. Paul Harasymowycz, renowned ophthalmologist and recognized innovator in MIGS techniques, has joined Hexiris’s Scientific Committee.

“We are proud that Dr. Harasymowycz has agreed to join our scientific committee,” said Dr. Nir Shoham-Hazon, Co-Founder and Co-CEO of Hexiris. “His extensive knowledge of MIGS will greatly contribute to the efforts of our growing team of experts, as we advance the development of our game-changing patented MIGS device.”

Dr. Harasymowycz commented: “I am truly excited to be part of Hexiris’ journey to advance the development of their new innovative MIGS device. I believe the device has the potential to improve patients’ lives while helping ophthalmologists enhance patient care, which is of paramount importance to me.”

Dr. Paul Harasymowycz, MD is the Founder and Medical Director of the Bellevue Ophthalmology Clinics and the Montreal Glaucoma Institute, Associate Professor at the Université de Montreal and Adjunct Clinical Professor at McGill University, and has been a clinician and researcher at the CUO (Centre universitaire d’ophtalmologie) at the Guy-Bernier Research Centre since 2001. He was head of the glaucoma unit at the Université de Montréal for more than 12 years and is a faculty member of the International Congress of Glaucoma Surgery. He is also the Medical Director of the Quebec Glaucoma Foundation, which was created in 2007 to promote research into the disease and raise awareness to encourage early detection among those at risk. His research focuses on glaucoma screening, new diagnostic and ocular imaging technologies, and new surgical treatments for glaucoma and cataract surgery. He is frequently asked to present and teach new surgical techniques and treatments at national and international congresses, and is recognized as an innovator in MIGS techniques.

Over the past 20 years, Dr. Harasymowycz has distinguished himself through his extensive research and more than 90 publications in national and international scientific journals, and book chapters on glaucoma. As an expert and enthusiast, he teaches externs, residents, fellows and other healthcare professionals.

Hexiris MIGS Solution
The Hexiris MIGS Solution consists of a specialized medical device and process that is designed to be a safe, fast, easy, and less invasive treatment. The process aims at increasing patient satisfaction, present better patient recovery, and increase the sustainability of a health system under pressure from an ageing population. As a result, the Hexiris MIGS Solution is expected to generate considerable cost benefits for the health system.

First Injectable Ocular Implant
The Hexiris patented ocular implant device is a medical game-changer as the first injectable ocular implant that can be processed under an office slit lamp without the complexity and cost of an operating room.

In-Office MIGS
The Hexiris device will be the first of its generation to take glaucoma surgery out of the surgical unit and make it a simple outpatient procedure. The procedure can be performed with a slit lamp by a certified ophthalmologist.

The first comprehensive solution of its kind
This ground-breaking technology and process will be the first of its kind, as there is no current FDA-approved, ab-externo MIGS devices (injected from the outside of the eye inward) on the market.

About Hexiris
Hexiris Inc. is a medical device company aimed at advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS). The company’s goal is to provide better access to MIGS for comprehensive ophthalmologists and take glaucoma surgery out of the operating room. To do so, Hexiris is designing and engineering a first-of-its-kind advanced technology device for office-based Minimally Invasive Glaucoma Surgeries (MIGS).

For more information about Hexiris and the innovative Hexiris MIGS solution, please visit the company’s website, at

Hexiris Inc.
Nir Shoham-Hazon
Chief Executive Officer

Forward-Looking Statements
This press release may include estimates, projections and other statements containing forward-looking information (“forward-looking statements”) within the meaning of the Securities Act (Ontario) and other provincial securities law in Canada. These forward-looking statements include, among others, statements with respect to the Company’s objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective” and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Risk factors include, but are not limited to: the Company’s limited operating history; uncertain market acceptance of the Company’s products; technology changes; competition; changes in applicable law; changes in the Company’s business strategy or development plans; the ability of the Company to attract substantial additional capital; the ability to attract and retain qualified personnel; liability and other claims asserted against the Company; and other factors. The foregoing list of important factors that may affect future results is not exhaustive. When reviewing the Company’s forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. All estimates, projections, and other forward-looking statements have been prepared by the Company on assumptions management considers reasonable at the date the statements are made. While the Company considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking statements. Many assumptions are based on factors and events that are not within the control of the Company and there is no assurance they will prove to be correct. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or results or otherwise. None of the Company or its affiliated or related partnerships and corporations or their respective directors, officers, partners, employees, agents or representatives makes any representation or warranty as to the accuracy or completeness of the press release or any statements, estimates or projections, and none will assume any liability for any representations (express or implied) contained in, or for any omissions from, the press release. Any representations concerning the Company or its business will only be made by the Company in a definitive agreement documenting a transaction between the Company and a prospective party.

A photo accompanying this announcement is available at

Primary Logo

Hexiris Inc.

Hexiris Welcomes Dr. Paul Harasymowycz to Its Scientific Committee